Physician profile
Avner Griver
NPI 1558361790
$7,849.28
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,703 · 2020: $850 · 2021: $3,112 · 2022: $790 · 2023: $282 · 2024: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,101.23 | 2021-2022 | |
| Vertiflex, INC. | $1,978.81 | 2019 | |
| Collegium Pharmaceutical, INC. | $424.39 | 2019-2023 | Xtampza |
| Medtronic, INC. | $415.51 | 2021-2023 | Intellis Adaptivestim, Accurian |
| Medtronic USA, INC. | $286.75 | 2019-2020 | |
| Abbvie INC. | $255.78 | 2019-2023 | |
| Si-Bone, INC. | $252.24 | 2019-2021 | |
| Boston Scientific Corporation | $248.03 | 2019-2023 | Superion Indirect Decompression System |
| Teva Pharmaceuticals USA, INC. | $211.84 | 2019-2023 | Austedo Xr, Austedo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.81 | 2019-2022 | |
| Pfizer INC. | $180.50 | 2019-2021 | |
| Daiichi Sankyo INC. | $149.14 | 2019 | |
| Lilly USA, LLC | $127.53 | 2019-2022 | |
| Amgen INC. | $115.50 | 2020-2021 | |
| Painteq LLC | $113.07 | 2024 | Painteq |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $99.27 | 2019 | |
| Allergan, INC. | $91.35 | 2020-2022 | |
| Grt US Holding, INC. | $84.30 | 2020-2022 | |
| Lundbeck LLC | $79.47 | 2022-2023 | Vyepti |
| Almatica Pharma LLC | $65.07 | 2022-2023 | Gralise |
| Biodelivery Sciences International, INC. | $64.71 | 2020-2021 | |
| Vertos Medical, INC. | $36.80 | 2022 | |
| Scilex Pharmaceuticals INC. | $31.68 | 2019-2021 | |
| Ibsa Pharma INC. | $30.35 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $29.24 | 2019 | |
| West Therapeutics Development, LLC | $29.22 | 2019 | |
| Nevro Corp. | $21.20 | 2020 | |
| Bioventus LLC | $19.79 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.01 | 2021 | |
| Ferring Pharmaceuticals INC. | $15.98 | 2021 | |
| Kaleo, INC. | $15.81 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.81 | 2019 | |
| Tersera Therapeutics LLC | $15.01 | 2019 | |
| Avanos Medical | $14.85 | 2022 | |
| Forte Bio-Pharma LLC | $11.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avner Griver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.